Welsis Corp.
WLSSAbout the company
Welsis Corp. does not have significant operations. It intends to enter the cryptocurrency and blockchain industry by launching TokenTraders.net, a crypto-exchange site. The company was incorporated in 2021 and is based in Philadelphia, Pennsylvania.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
2 / 14
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-01-13 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 1✗ 34▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/5 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)0/5 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROEN/A (negative equity)✗Lynch> 15%EBIT / Enterprise Value-3.0%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-3.0%, ROC=None✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-2798.06%✗PiotroskiROA > 0ROA Change YoY✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-2302.77%, ROA=-2798.06%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity✗Dreman> 12%Margin of Safety✗PabraiP/B < 1.5 or P/E < 15Return on Equity✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue✗Ackman>= 15%Net Income / Shareholders Equity✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-3.67%; #3741/6340 (top 59.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+0.00%; #3481/3702 (top 94.0%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-11.6070; #5706/5884 (top 97.0%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/5 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Debt & Leverage0% pass✗ 15▾
All 12 investors flag WLSS's debt & leverage
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -5.0x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / EquityN/A (negative equity)✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change✗PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.03✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt LevelsN/A (non-positive equity)✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-5.0x, D/EBITDA=N/A (D&A unavailable)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-3.0%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-3.0%, ROC=None✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per ShareN/A (negative BVPS)✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation Reasonableness✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF Yield✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical Average✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($0.60)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-3.67%; #3741/6340 (top 59.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization-0.0910; #5697/6449 (top 88.3%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0000; #5080/5247 (top 96.8%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-75.90%; #5763/6202 (top 92.9%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy✗BuffettPositive and growingFCF Positive and Growing$-0.1M✗LynchPositive and growingOperating Cash Flow$-0.0M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-2302.77%, ROA=-2798.06%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF Yield✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/1 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap✗Ackman>= 4%Price / FCF per Share✗Ackman<= 25Positive Operating Cash Flow frequency0/5 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction$0.00 (2021) -> $-0.02 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-93.5%✗Ackman>= 5%Positive EPS Growth Frequency0/4 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✓ 1✗ 10▾
No clean pass — all 8 investors flag at least one efficiency criterion
Current Ratio0.03✗Graham>= 2.0ROIC (3-5 yr avg)✗Buffett> 10%ROIC - WACC✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)✗Greenblatt> 25%Current Ratio Change YoY0.00 -> 0.03✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY✗PiotroskiImproved YoYCurrent Assets / Current Liabilities0.03✗Dreman> 1.5Return on Invested CapitalN/A (non-positive invested capital)✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years - Verdicts0% pass✗ 14▾
Split decision: 14 FAIL · 2 NEUTRAL
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (0/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Retired 0.0% of shares last year, 0.0% over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2025-12-31 2025-01-01 – 2025-12-31 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, revenue, net income, operating income, gross profit, ebit, interest expense. | Q1 FY 2026 2025-10-01 – 2025-12-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|
| Market Cap | $1.7Mcurrent | -- | $5.5Mest. | $4.4Mest. | $5.1Mest. | -- | -- |
| Revenue | $0 | $0 | $0↓100% | $2.0K↓94% | $30.9K | $0 | $0 |
| Operating Income | -$35.1K↑48% | -$6.8K↑69% | -$50.6K↑13% | -$57.9K↓56% | -$37.1K↑13% | -$42.8K↑25% | -$56.9K |
| Net Income | -$46.5K↓30% | -$10.0K↑59% | -$60.7K↓146% | -$24.7K↑40% | -$41.1K↑4% | -$42.8K↑25% | -$56.9K |
| EPS (Diluted) | -- | $0.00↑100% | $-0.02 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Margin | — | — | — | 100.0%↑94% | 51.5% | — | — |
| Operating Margin | — | — | — | -2894.9%↓2313% | -120.0% | — | — |
| ROE | 29.0%↓8% | — | 40.4%↑47% | 27.5%↓21% | 34.8%↓37% | 55.6%↓45% | 100.4% |
| Total Debt | $40.0K | $40.0K | $40.0K | $40.0K↓50% | $80.0K↑100% | $40.0K | $40.0K |
| Shareholders' Equity | -$160.4K↓41% | -$160.4K↓41% | -$150.3K↓68% | -$89.6K↑24% | -$118.0K↓53% | -$76.9K↓36% | -$56.7K |
| Current Ratio | 0.01↓70% | 0.01↓70% | 0.03 | 0.00↓100% | 0.07↓70% | 0.22 | 0.00 |
| Debt / Equity | -0.25↑29% | -0.25↑29% | -0.27↑40% | -0.45↑34% | -0.68↓30% | -0.52↑26% | -0.71 |
| Operating Cash Flow | -$51.2K↓76% | -$10.5K↓13% | -$49.9K↓67% | -$30.0K↓37% | -$21.9K↑44% | -$38.8K↑31% | -$56.6K |
| Free Cash Flow | -- | -- | -- | -- | -$61.9K | -- | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Healthcare
WLSS vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc.HCA | $104.2B | $499.05 | $75.6B | $6.8B | -112.6% | -7.71 | 13.0% | 0.97 | 1/9 | 5/9 | 3/7 | 1/3 | F-Score 6 | 4/11 |
| TENET HEALTHCARE CORPTHC | $22.8B | $286.03 | $21.3B | $2.4B | 56.1% | 3.12 | 16.5% | 1.76 | 1/9 | 4/9 | 3/7 | 3/3 | F-Score 6 | 5/11 |
| Guardant Health, Inc.GH | $20.5B | $151.70 | $982.0M | $416.3M | 419.2% | -15.14 | -44.5% | 4.84 | 2/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 2/11 |
| EXACT SCIENCES CORPEXAS | $20.0B | $104.91 | $3.2B | $207.9M | -8.7% | 0.00 | -6.4% | 2.43 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 7 | 3/11 |
| Fresenius Medical Care AGFMS | $11.4B | $22.03 | $23.1B | $1.1B | 7.4% | 0.81 | 9.3% | 1.26 | 5/9 | 2/9 | 1/7 | 0/3 | F-Score 8 | 5/11 |
| UNIVERSAL HEALTH SERVICES INCUHS | $11.2B | $194.07 | $17.4B | $1.5B | 20.5% | 0.65 | 11.5% | 1.05 | 4/9 | 6/9 | 5/7 | 1/3 | F-Score 7 | 6/11 |
| DAVITA INC.DVA | $11.0B | $174.56 | $13.6B | $746.8M | -114.7% | -15.78 | 15.0% | 1.29 | 1/9 | 4/9 | 2/7 | 1/3 | F-Score 7 | 3/11 |
| CHEMED CORPCHE | $7.1B | $548.20 | $2.5B | $265.2M | 27.1% | — | 13.4% | 1.05 | 4/9 | 7/9 | 3/7 | 1/3 | F-Score 6 | 6/11 |